(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
---|---|---|---|---|---|---|---|---|---|
Turnover | 67.61%1.67B | 114.44%2.12B | 201.57%993.47M | 301.56%487.59M | 218.33%990.42M | --329.44M | --121.43M | 222.91%311.13M | --96.35M |
Operating income | 67.61%1.67B | 114.44%2.12B | 201.57%993.47M | 301.56%487.59M | 218.33%990.42M | 329.44M | 121.43M | 222.91%311.13M | 96.35M |
Cost of sales | -47.88%-1.13B | -114.48%-1.56B | -238.86%-764.07M | -389.90%-369.22M | -269.03%-729.34M | ---225.48M | ---75.37M | -123.90%-197.64M | ---88.27M |
Operating expenses | -47.88%-1.13B | -114.48%-1.56B | -238.86%-764.07M | -389.90%-369.22M | -269.03%-729.34M | -225.48M | -75.37M | -123.90%-197.64M | -88.27M |
Gross profit | 133.36%535.33M | 114.32%559.56M | 120.67%229.4M | 157.01%118.38M | 130.04%261.08M | 103.96M | 46.06M | 1,304.45%113.49M | 8.08M |
Selling expenses | -310.91%-23.93M | -73.57%-15.22M | -40.25%-5.82M | -23.31%-2.15M | -332.40%-8.77M | ---4.15M | ---1.75M | -324.27%-2.03M | ---478K |
Administrative expenses | -76.72%-75.53M | -151.91%-123.97M | -180.29%-42.74M | -97.30%-16.32M | -76.65%-49.21M | ---15.25M | ---8.27M | -189.95%-27.86M | ---9.61M |
Research and development expenses | -59.99%-47.59M | -127.13%-76.87M | -169.00%-29.75M | -271.47%-16.25M | -144.97%-33.84M | ---11.06M | ---4.38M | -239.02%-13.82M | ---4.08M |
Impairment and provision | -112.99%-3.17M | 150.71%21.99M | 719.29%24.38M | 166.79%15.39M | -310.77%-43.37M | --2.98M | --5.77M | -3,553.29%-10.56M | ---289K |
-Other impairment is provision | -112.99%-3.17M | 150.71%21.99M | 719.29%24.38M | 166.79%15.39M | -310.77%-43.37M | --2.98M | --5.77M | -3,553.29%-10.56M | ---289K |
Special items of operating profit | 382.33%176.85M | -107.06%-5.14M | -17.59%36.67M | -86.50%370K | 797.84%72.82M | --44.49M | --2.74M | -79.06%8.11M | --38.74M |
Operating profit | 164.91%561.97M | 81.34%360.35M | 75.37%212.14M | 147.44%99.41M | 195.07%198.72M | 120.96M | 40.18M | 108.08%67.35M | 32.37M |
Financing cost | 56.24%-249K | 74.55%-742K | 63.83%-569K | 10.11%-427K | -491.48%-2.92M | ---1.57M | ---475K | ---493K | ---- |
Earning before tax | 165.50%561.72M | 83.66%359.61M | 77.21%211.57M | 149.32%98.98M | 192.88%195.8M | 119.39M | 39.7M | 106.55%66.85M | 32.37M |
Tax | -113.91%-73.49M | -89.85%-76.07M | -62.64%-34.35M | -105.02%-18.31M | -236.07%-40.07M | ---21.12M | ---8.93M | -96.52%-11.92M | ---6.07M |
After-tax profit from continuing operations | 175.50%488.23M | 82.07%283.54M | 80.34%177.21M | 162.18%80.67M | 183.51%155.73M | 98.27M | 30.77M | 108.87%54.93M | 26.3M |
Earning after tax | 175.50%488.23M | 82.07%283.54M | 80.34%177.21M | 162.18%80.67M | 183.51%155.73M | 98.27M | 30.77M | 108.87%54.93M | 26.3M |
Profit attributable to shareholders | 175.50%488.23M | 82.07%283.54M | 80.34%177.21M | 162.18%80.67M | 183.51%155.73M | 98.27M | 30.77M | 108.87%54.93M | 26.3M |
Basic earnings per share | 127.78%0.41 | 55.56%0.28 | 28.57%0.18 | 60.00%0.08 | 100.00%0.18 | 0.14 | 0.05 | 125.00%0.09 | 0.04 |
Diluted earnings per share | 123.53%0.38 | 44.44%0.26 | 21.43%0.17 | 60.00%0.08 | 100.00%0.18 | 0.14 | 0.05 | 125.00%0.09 | 0.04 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data